Comparison of Accelerated and Rapid Schedules for Monovalent Hepatitis B and Combined Hepatitis a/B Vaccines in Children With Cancer

Köksal, Yavuz; Varan, Ali; Aydın, Burça; Sarı, Neriman; Yazıcı, Nalan; Yalçın, Bilgehan; Kutluk, Tezer; Akyüz, Canan; Büyükpamukçu, Münevver

doi:10.1080/08880010701703511

Cited by 11 publications

(6 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, during chemotherapy, vaccines containing inactivated organisms or purified antigens are not contraindicated [81][82][83][84][85][86][87][88]. In contrast, vaccination with live attenuated viruses are contraindicated to avoid risks of vaccination disease and/or for lack of data of effectiveness [89,90].…”

Section: Vaccination During Chemotherapymentioning

confidence: 99%

Vaccination in immunocompromised host: Recommendations of Italian Primary Immunodeficiency Network Centers (IPINET)

Martire

Azzari

Badolato

et al. 2018

Vaccine

View full text Add to dashboard Cite

Infectious complications are a major cause of morbidity and mortality in patients with primary or secondary immunodeficiency. Prevention of infectious diseases by vaccines is among the most effective healthcare measures mainly for these subjects. However immunocompromised people vary in their degree of immunosuppression and susceptibility to infection and, therefore, represent a heterogeneous population with regard to immunization. To date there is no well- established evidence for use of vaccines in immunodeficient patients, and indications are not clearly defined even in high-quality reviews and in most of the guidelines prepared to provide recommendations for the active vaccination of immunocompromised hosts. The aim of this document is to issue recommendations based on published literature and the collective experience of the Italian primary immunodeficiency centers, about how and when vaccines can be used in immunocompromised patients, in order to facilitate physician decisions and to ensure the best immune protection with the lowest risk to the health of the patient.

show abstract

Section: Vaccination During Chemotherapymentioning

confidence: 99%

Vaccination in immunocompromised host: Recommendations of Italian Primary Immunodeficiency Network Centers (IPINET)

Martire

Azzari

Badolato

et al. 2018

Vaccine

View full text Add to dashboard Cite

show abstract

“…For HAV and HPV, the recommendations are based mainly on the opinion of experts because no specific data have so far been produced in these settings [22, 28] (C, III).…”

Section: Resultsmentioning

confidence: 99%

Guidelines on Vaccinations in Paediatric Haematology and Oncology Patients

Cesaro

Giacchino

Fioredda

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

Objective. Vaccinations are the most important tool to prevent infectious diseases. Chemotherapy-induced immune depression may impact the efficacy of vaccinations in children. Patients and Methods. A panel of experts of the supportive care working group of the Italian Association Paediatric Haematology Oncology (AIEOP) addressed this issue by guidelines on vaccinations in paediatric cancer patients. The literature published between 1980 and 2013 was reviewed. Results and Conclusion. During intensive chemotherapy, vaccination turned out to be effective for hepatitis A and B, whilst vaccinations with toxoid, protein subunits, or bacterial antigens should be postponed to the less intensive phases, to achieve an adequate immune response. Apart from varicella, the administration of live-attenuated-virus vaccines is not recommended during this phase. Family members should remain on recommended vaccination schedules, including toxoid, inactivated vaccine (also poliomyelitis), and live-attenuated vaccines (varicella, measles, mumps, and rubella). By the time of completion of chemotherapy, insufficient serum antibody levels for vaccine-preventable diseases have been reported, while immunological memory appears to be preserved. Once immunological recovery is completed, usually after 6 months, response to booster or vaccination is generally good and allows patients to be protected and also to contribute to herd immunity.

show abstract

“…A super-accelerated vaccination scheme was designed based on the previous reports of significant acute and long-term protective antibody levels following multiple, double doses of vaccination during chemotherapy in children with cancer. 14 ,15, 16 Three doses (at days 0-5, 8-12, and 28-33) of booster recombinant HBV vaccines (Engerix-B, GlaxoSmithKline Pharmaceuticals Limited) were administered to children with cancer who were HBV seronegative (negative for HBsAg and anti-HBs Ab) at diagnosis.…”

Section: Methodsmentioning

confidence: 99%

“… 4 , 13 Alternative accelerated or super-accelerated schedules were reported to be feasible to get serologic response during chemotherapy or other conditions with altered immunity. 14 ,15, 16 …”

Section: Introductionmentioning

confidence: 99%

Hepatitis B Vaccination in Children With Ongoing Cancer Treatment: A Safety and Efficacy Study of Super-Accelerated Vaccination Scheme

Ocak¹,

Karaman²,

Vural³

et al. 2023

Turk Arch Pediatrics

View full text Add to dashboard Cite

Objective: Children with cancer have an increased risk for hepatitis B virus (HBV) infections due to chemotherapy-induced secondary immunodeficiency and frequent blood transfusions. The aim of this study is to evaluate the efficacy and safety of hepatitis B vaccination during the intensive induction chemotherapy in children with cancer found to be seronegative for hepatitis B on admission. Materials and Methods: Children newly diagnosed with cancer were evaluated for the presence of hepatitis B surface antigen (HBsAg) and antibody on admission. The children negative for both were included in the study. A super-accelerated vaccination scheme (3 booster doses at days 1-5, 8-12, and 28-33) was administered to these seronegative children concurrently with induction chemotherapy. Antibody response was checked 4-8 weeks after the last vaccination and 6 months after the end of the treatment. Results: Eleven out of 122 children were seronegative for hepatitis B on admission (9%). Acute lymphoblastic leukemia, lymphoma, and solid tumors were diagnosed in 5, 4, and 2 children, respectively. Complete seroconversion was achieved in 4-8 weeks after the last vaccination with high titers of anti-HBs antibody, and all patients remained antibody-positive until 6 months after the completion of chemotherapy. Conclusion: The risk of transfusion-related infections increases with a number of transfused products and donor exposures, and it is more significant for immunosuppressed children with hematologic and oncologic malignancies. Hepatitis B vaccination could safely be applied with brisk and sustained responses in this vulnerable population, based on the local epidemiological data.

show abstract

Comparison of Accelerated and Rapid Schedules for Monovalent Hepatitis B and Combined Hepatitis a/B Vaccines in Children With Cancer

Cited by 11 publications

References 24 publications

Vaccination in immunocompromised host: Recommendations of Italian Primary Immunodeficiency Network Centers (IPINET)

Vaccination in immunocompromised host: Recommendations of Italian Primary Immunodeficiency Network Centers (IPINET)

Guidelines on Vaccinations in Paediatric Haematology and Oncology Patients

Hepatitis B Vaccination in Children With Ongoing Cancer Treatment: A Safety and Efficacy Study of Super-Accelerated Vaccination Scheme

Contact Info

Product

Resources

About